title: Aerosol droplet delivery of mesoporous silica nanoparticles: A strategy for respiratory-based therapeutics.
abstract: A highly versatile nanoplatform that couples mesoporous silica nanoparticles (MSNs) with an aerosol technology to achieve direct nanoscale delivery to the respiratory tract is described. This novel method can deposit MSN nanoparticles throughout the entire respiratory tract, including nasal, tracheobronchial and pulmonary regions using a water-based aerosol. This delivery method was successfully tested in mice by inhalation. The MSN nanoparticles used have the potential for carrying and delivering therapeutic agents to highly specific target sites of the respiratory tract. The approach provides a critical foundation for developing therapeutic treatment protocols for a wide range of diseases where aerosol delivery to the respiratory system would be desirable.
  
  
  BACKGROUND
  Delivery of drugs via the respiratory tract is an attractive route of administration. In this article, the authors described the design of mesoporous silica nanoparticles which could act as carriers for drugs. The underlying efficacy was successfully tested in a mouse model. This drug-carrier inhalation nanotechnology should potentially be useful in human clinical setting in the future.
authors.affiliation: Center for Health and the Environment, University of California, Davis, USA; Department of Nutritional Sciences and Toxicology, University of California, Berkeley, USA; Department of Chemical Engineering and Materials Science, University of California, Davis, USA. Electronic address: xl2479@columbia.edu.
authors.forename: Xueting
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Chemistry and Biochemistry, University of California, Los Angeles, USA. Electronic address: mxue@chem.ucla.edu.
authors.forename: Min
authors.initials: M
authors.lastname: Xue
authors.affiliation: Center for Health and the Environment, University of California, Davis, USA; Department of Molecular Biosciences, University of California, Davis, USA. Electronic address: ograabe@ucdavis.edu.
authors.forename: Otto G
authors.initials: OG
authors.lastname: Raabe
authors.affiliation: Cancer Research Laboratory Molecular Imaging Center, University of California, Berkeley, USA. Electronic address: hollya@berkeley.edu.
authors.forename: Holly L
authors.initials: HL
authors.lastname: Aaron
authors.affiliation: Environmental Health Sciences, School of Public Health, University of California, Berkeley, USA. Electronic address: eeisen@berkeley.edu.
authors.forename: Ellen A
authors.initials: EA
authors.lastname: Eisen
authors.affiliation: Center for Health and the Environment, University of California, Davis, USA. Electronic address: james.evans@pnnl.gov.
authors.forename: James E
authors.initials: JE
authors.lastname: Evans
authors.affiliation: Department of Chemical Engineering and Materials Science, University of California, Davis, USA. Electronic address: fahayes@ucdavis.edu.
authors.forename: Fred A
authors.initials: FA
authors.lastname: Hayes
authors.affiliation: Department of Functional, Morphological and Regulatory Science, Tottori University, Yonago, Japan. Electronic address: sumire@med.tottori-u.ac.jp.
authors.forename: Sumire
authors.initials: S
authors.lastname: Inaga
authors.affiliation: Department of Nutritional Sciences and Toxicology, University of California, Berkeley, USA. Electronic address: tagmount@berkeley.edu.
authors.forename: Abderrahmane
authors.initials: A
authors.lastname: Tagmount
authors.affiliation: Department of Animal Medical Science, Kyoto Sangyo University, Kyoto, Japan. Electronic address: mtakex@cc.kyoto-su.ac.jp.
authors.forename: Minoru
authors.initials: M
authors.lastname: Takeuchi
authors.affiliation: Department of Nutritional Sciences and Toxicology, University of California, Berkeley, USA. Electronic address: vulpe@berkeley.edu.
authors.forename: Chris
authors.initials: C
authors.lastname: Vulpe
authors.affiliation: Department of Chemistry and Biochemistry, University of California, Los Angeles, USA. Electronic address: Zink@chem.ucla.edu.
authors.forename: Jeffrey I
authors.initials: JI
authors.lastname: Zink
authors.affiliation: Department of Chemical Engineering and Materials Science, University of California, Davis, USA. Electronic address: shrisbud@ucdavis.edu.
authors.forename: Subhash H
authors.initials: SH
authors.lastname: Risbud
authors.affiliation: Center for Health and the Environment, University of California, Davis, USA. Electronic address: kepinkerton@ucdavis.edu.
authors.forename: Kent E
authors.initials: KE
authors.lastname: Pinkerton
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D008171:Lung Diseases / Q000628:therapy; D008297:Male; D051379:Mice; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles; D012822:Silicon Dioxide / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000336:Aerosols; D012822:Silicon Dioxide
keywords: Aerosol droplets; Mesoporous silica nanoparticles; Respiratory tract
references.citation: Chem Soc Rev. 2012 Apr 7;41(7):2590-605
references.pmid: 22216418
references.citation: Nanoscale. 2012 Feb 7;4(3):970-5
references.pmid: 22200056
references.citation: Pharm Res. 2012 Jun;29(6):1637-49
references.pmid: 22281760
references.citation: J Biomed Nanotechnol. 2012 Aug;8(4):624-32
references.pmid: 22852472
references.citation: Virol J. 2012;9:108
references.pmid: 22691538
references.citation: J Am Chem Soc. 2012 Sep 26;134(38):15790-804
references.pmid: 22924492
references.citation: Nat Med. 2012 Oct;18(10):1580-5
references.pmid: 22983397
references.citation: Integr Biol (Camb). 2013 Jan;5(1):19-28
references.pmid: 23042147
references.citation: Adv Drug Deliv Rev. 2013 May;65(5):689-702
references.pmid: 22921598
references.citation: Crit Rev Biotechnol. 2013 Sep;33(3):229-45
references.pmid: 22724458
references.citation: Acc Chem Res. 2013 Mar 19;46(3):792-801
references.pmid: 23387478
references.citation: Biomaterials. 2013 Dec;34(37):9401-12
references.pmid: 24016854
references.citation: Pharmacol Ther. 2013 Nov;140(2):176-85
references.pmid: 23811125
references.citation: Ann Allergy Asthma Immunol. 1998 Jun;80(6):499-508
references.pmid: 9647274
references.citation: Toxicol Appl Pharmacol. 1973 Oct;26(2):264-73
references.pmid: 4751105
references.citation: Biotechniques. 2001 Dec;31(6):1272, 1274-6, 1278
references.pmid: 11768655
references.citation: Nat Rev Cancer. 2005 Mar;5(3):161-71
references.pmid: 15738981
references.citation: Small. 2009 Jan;5(1):57-62
references.pmid: 19051185
references.citation: Small. 2010 Jun 6;6(11):1185-90
references.pmid: 20461725
references.citation: Small. 2010 Sep 20;6(18):2041-9
references.pmid: 20721949
references.citation: ACS Nano. 2011 May 24;5(5):4131-44
references.pmid: 21524062
references.citation: Nanoscale. 2011 Jul;3(7):2801-18
references.pmid: 21547299
references.citation: J Drug Target. 2011 Dec;19(10):900-14
references.pmid: 21981718
references.citation: Antimicrob Agents Chemother. 2012 May;56(5):2535-45
references.pmid: 22354311